

Panion reports on safety study in dogs – no untoward effects

Panion Animal Health AB develops a unique gene therapy treatment for dogs with epilepsy. Panion's treatment is based on the gene therapeutic technology that CombiGene has developed and that CombiGene has out licensed to Panion for use within in veterinary medicine.

Panions safety study was conducted under the lead of Associate Professor David Woldbye at University of Copenhagen. The first preliminary results show that all treated dogs have successfully completed the study without observable adverse reactions.

CombiGene wants to take this opportunity to congratulate our colleagues at Panion for this successful study!

About CombiGene AB

By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace Spotlight. www.combigene.com

For further information:

CombiGene AB (publ)
Jan Nilsson, CEO
Phone: +46 (0)704 66 31 63
Email: jan.nilsson@combigene.com

MORE FROM THE COMPANY is a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and PRESS RELEASES are available at www.combigene.com

www.combigene.com

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden
info@combigene.com